HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

YZYBIO-B

3.600

0.000

Volume:- -

Turnover:- -

Market Cap:698.40M

PE:-8.24

High:3.600

Open:3.600

Low:3.600

Close:3.600

52wk High:8.400

52wk Low:3.600

Shares:194.00M

HK Float Shares:179.48M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.437

ROE:-704.81%

ROA:-22.74%

PB:-11.29

PE(LYR):-8.24

PS:8.95

Loading ...

Overview Company News Filings

YZYBIO-B schedules 28 Aug 2026 board session to approve 1H 2026 interim results

Bulletin Express

Wuhan YZY Biopharma Schedules Board Meeting to Review Interim Results

YZY Biopharma Reports No Change in Share Capital for July 2026; 1.25 Million Options Outstanding

Bulletin Express

YZYBIO-B (02496) to Present Clinical Data for M701 at 2026 ASCO Annual Meeting

Wuhan YZY Biopharma says Phase III M701 trial prolongs puncture-free survival in malignant ascites

YZYBIO-B Announces Supervisor Transition: Dr. Shi Jian Steps Down, Ms. Fang Lijuan Elected as Employee Representative

Bulletin Express

YZYBIO-B (02496) Announces Election of Fang Lijuan as Second-Term Employee Representative Supervisor

Wuhan Yzy Biopharma names Fang Lijuan employee representative supervisor, replacing Shi Jian

Wuhan YZY Biopharma’s NDA for Bispecific Antibody M701 Wins NMPA Acceptance

Bulletin Express

YZYBIO-B Receives NMPA Acceptance for M701 New Drug Application Targeting Malignant Ascites

BRIEF-Wuhan Yzy Biopharma Co Says NDA For M701 Accepted By NMPA For Treatment Of Malignant Ascites

Wuhan YZY Biopharma says China regulator accepts M701 NDA for malignant ascites

Wuhan YZY Biopharma Co Ltd - Nda for M701 Accepted by Nmpa for Treatment of Malignant Ascites

THOMSON REUTERS

YZYBIO-B Keeps Share Capital Steady in April; 1.25 Million H-Share Options Outstanding

Bulletin Express

YZY Biopharma’s M701 Clinical Data Earns Dual Slots at 2026 ASCO Annual Meeting

Bulletin Express

YZYBIO-B (02496): Two M 701 Research Findings Selected for Presentation at 2026 ASCO Annual Meeting

Wuhan YZY Biopharma says M701 Phase III malignant ascites data selected for ASCO oral presentation

YZYBIO releases 2025 ESG report: RMB 78.20 million R&D spend, 9% drop in per-capita carbon emissions

Bulletin Express

友芝友生物2025年收入下滑、研发投入减少并聚焦双特异抗体管线

Bulletin Express

Wuhan YZY Biopharma publishes 2025 annual report

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/02496/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"02496","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02496\",,,,,undefined,":{"symbol":"02496","market":"HK","secType":"STK","nameCN":"YZYBIO-B","latestPrice":3.6,"timestamp":1787275207109,"preClose":3.6,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":179479113,"shares":194000000,"eps":-0.437103,"marketStatus":"Market Closed","change":0,"latestTime":"08-21 09:20:07","open":3.6,"high":3.6,"low":3.6,"amount":0,"amplitude":0,"askPrice":3.6,"askSize":400,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.486413,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":7,"adr":0,"listingDate":1695571200000,"exchange":"SEHK","adjPreClose":3.6,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"volumeRatio":0,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02496\",,,,,undefined,":{"symbol":"02496","floatShares":179479113,"roa":"-22.74%","roe":"-704.81%","lyrEps":-0.437103,"shares":194000000,"dividePrice":0,"high":3.6,"amplitude":0,"preClose":3.6,"low":3.6,"week52Low":3.6,"pbRate":"-11.29","psRate":"8.95","week52High":8.4,"institutionHeld":0,"latestPrice":3.6,"committee":-1,"eps":-0.437103,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.486413,"open":3.6,"prevYearClose":8.02,"prevWeekClose":3.6,"prevMonthClose":3.69,"prevQuarterClose":3.8,"fiveDayClose":3.6,"twentyDayClose":3.69,"sixtyDayClose":5.16,"earningDate":1787846400000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02496\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"02496","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787880600000,"name":null,"time":"","dateTimestamp":1787846400000,"actualEps":null},{"date":"2026-03-27","symbol":"02496","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774575000000,"name":null,"time":"","dateTimestamp":1774540800000,"actualEps":null},{"date":"2025-08-26","symbol":"02496","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756171800000,"name":null,"time":"","dateTimestamp":1756137600000,"actualEps":null},{"date":"2025-03-28","symbol":"02496","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1743125400000,"name":null,"time":"Post-Mkt","dateTimestamp":1743091200000,"actualEps":null},{"date":"2024-08-29","symbol":"02496","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724895000000,"name":null,"time":"","dateTimestamp":1724860800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02496\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02496\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02496\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02496","date":"2026-08-21","current":-7.401118,"percent":0.777622,"low":-18.565593,"twenty":-12.507767,"median":-8.246013,"eighty":-6.973742,"high":-3.741546,"avg":-9.382224,"sd":3.599022,"marketCap":697857120},"quantilePoints":[{"date":"2023-09-22","current":-15.261024,"twenty":-15.274233,"median":-15.26928,"eighty":-15.264326,"marketCap":3088019200},{"date":"2023-09-29","current":-15.292224,"twenty":-17.099581,"median":-15.293234,"eighty":-15.280473,"marketCap":3049418960},{"date":"2023-10-06","current":-15.493216,"twenty":-15.501023,"median":-15.292224,"eighty":-15.050323,"marketCap":3088019200},{"date":"2023-10-13","current":-15.380625,"twenty":-15.493216,"median":-15.348538,"eighty":-15.261024,"marketCap":3060999032},{"date":"2023-10-20","current":-10.535817,"twenty":-15.418704,"median":-15.300038,"eighty":-14.801616,"marketCap":2093571360},{"date":"2023-10-27","current":-9.759574,"twenty":-15.417248,"median":-15.292224,"eighty":-11.937608,"marketCap":1938492000},{"date":"2023-11-03","current":-9.733728,"twenty":-15.412338,"median":-15.155674,"eighty":-10.478048,"marketCap":1938492000},{"date":"2023-11-10","current":-8.275398,"twenty":-15.390041,"median":-14.508961,"eighty":-9.494912,"marketCap":1647718200},{"date":"2023-11-17","current":-8.703164,"twenty":-15.38145,"median":-11.695259,"eighty":-8.750672,"marketCap":1748519784},{"date":"2023-11-24","current":-8.421561,"twenty":-15.329285,"median":-10.573898,"eighty":-8.701771,"marketCap":1705872960},{"date":"2023-12-01","current":-7.919793,"twenty":-15.30332,"median":-10.003273,"eighty":-8.541365,"marketCap":1610886852},{"date":"2023-12-08","current":-8.497372,"twenty":-15.294595,"median":-9.516549,"eighty":-8.420238,"marketCap":1721380896},{"date":"2023-12-15","current":-8.258301,"twenty":-15.292426,"median":-9.276148,"eighty":-8.274722,"marketCap":1682611056},{"date":"2023-12-22","current":-8.349506,"twenty":-15.280473,"median":-8.776546,"eighty":-8.277258,"marketCap":1700057484},{"date":"2023-12-29","current":-8.428335,"twenty":-15.270931,"median":-8.740745,"eighty":-8.306436,"marketCap":1725257880},{"date":"2024-01-05","current":-8.249766,"twenty":-15.218884,"median":-8.699682,"eighty":-8.272694,"marketCap":1676795580},{"date":"2024-01-12","current":-8.302569,"twenty":-15.000582,"median":-8.571321,"eighty":-8.275563,"marketCap":1688426532},{"date":"2024-01-19","current":-8.113537,"twenty":-14.743085,"median":-8.513713,"eighty":-8.272694,"marketCap":1647718200},{"date":"2024-01-26","current":-7.982332,"twenty":-14.471602,"median":-8.481448,"eighty":-8.258393,"marketCap":1614763836},{"date":"2024-02-02","current":-7.992522,"twenty":-13.915342,"median":-8.424948,"eighty":-8.196137,"marketCap":1614763836},{"date":"2024-02-09","current":-8.02019,"twenty":-12.050937,"median":-8.406699,"eighty":-8.080173,"marketCap":1628333280},{"date":"2024-02-16","current":-8.343013,"twenty":-11.339581,"median":-8.370574,"eighty":-8.105196,"marketCap":1694242008},{"date":"2024-02-23","current":-8.30086,"twenty":-10.803844,"median":-8.369483,"eighty":-8.124586,"marketCap":1676795580},{"date":"2024-03-01","current":-8.247733,"twenty":-10.604956,"median":-8.362825,"eighty":-8.153154,"marketCap":1667103120},{"date":"2024-03-08","current":-8.186551,"twenty":-10.543433,"median":-8.343013,"eighty":-8.173812,"marketCap":1655472168},{"date":"2024-03-15","current":-8.155425,"twenty":-10.30474,"median":-8.311389,"eighty":-8.173276,"marketCap":1647718200},{"date":"2024-03-22","current":-7.39462,"twenty":-9.857053,"median":-8.302569,"eighty":-8.105196,"marketCap":1492638840},{"date":"2024-03-28","current":-7.61103,"twenty":-9.744066,"median":-8.301568,"eighty":-8.043049,"marketCap":1531408680},{"date":"2024-04-05","current":-7.288366,"twenty":-9.690292,"median":-8.300787,"eighty":-8.021295,"marketCap":1512023760},{"date":"2024-04-12","current":-6.976051,"twenty":-9.494912,"median":-8.295352,"eighty":-7.983468,"marketCap":1448053524},{"date":"2024-04-19","current":-6.963318,"twenty":-9.388856,"median":-8.276973,"eighty":-7.977458,"marketCap":1444176540},{"date":"2024-04-26","current":-6.971914,"twenty":-9.296949,"median":-8.272018,"eighty":-7.930221,"marketCap":1444176540},{"date":"2024-05-03","current":-6.976736,"twenty":-9.241479,"median":-8.264756,"eighty":-7.6347,"marketCap":1444176540},{"date":"2024-05-10","current":-6.960212,"twenty":-8.933122,"median":-8.256463,"eighty":-7.598809,"marketCap":1444176540},{"date":"2024-05-17","current":-6.970443,"twenty":-8.807861,"median":-8.251559,"eighty":-7.39462,"marketCap":1444176540},{"date":"2024-05-24","current":-7.095514,"twenty":-8.76114,"median":-8.247733,"eighty":-7.267873,"marketCap":1444176540},{"date":"2024-05-31","current":-7.0883,"twenty":-8.730819,"median":-8.237322,"eighty":-7.171233,"marketCap":1444176540},{"date":"2024-06-07","current":-7.097101,"twenty":-8.707372,"median":-8.195562,"eighty":-7.097101,"marketCap":1444176540},{"date":"2024-06-14","current":-7.132215,"twenty":-8.698985,"median":-8.193432,"eighty":-7.097238,"marketCap":1449992016},{"date":"2024-06-21","current":-7.988022,"twenty":-8.625304,"median":-8.18531,"eighty":-7.098087,"marketCap":1620579312},{"date":"2024-06-28","current":-7.48471,"twenty":-8.574009,"median":-8.177364,"eighty":-7.098775,"marketCap":1517839236},{"date":"2024-07-05","current":-7.715801,"twenty":-8.562528,"median":-8.159606,"eighty":-7.101937,"marketCap":1564363044},{"date":"2024-07-12","current":-7.141207,"twenty":-8.536784,"median":-8.120442,"eighty":-7.107036,"marketCap":1449992016},{"date":"2024-07-19","current":-7.131527,"twenty":-8.514561,"median":-8.053748,"eighty":-7.107036,"marketCap":1448053524},{"date":"2024-07-26","current":-7.10513,"twenty":-8.504633,"median":-8.029564,"eighty":-7.105677,"marketCap":1448053524},{"date":"2024-08-02","current":-7.109273,"twenty":-8.491002,"median":-8.019114,"eighty":-7.105677,"marketCap":1448053524},{"date":"2024-08-09","current":-7.033842,"twenty":-8.475712,"median":-7.991974,"eighty":-7.097834,"marketCap":1442238048},{"date":"2024-08-16","current":-6.879903,"twenty":-8.451599,"median":-7.985142,"eighty":-7.095806,"marketCap":1411222176},{"date":"2024-08-23","current":-6.041633,"twenty":-8.425625,"median":-7.981406,"eighty":-7.090359,"marketCap":1244511864},{"date":"2024-08-30","current":-6.047183,"twenty":-8.418914,"median":-7.97694,"eighty":-7.085583,"marketCap":1219311468},{"date":"2024-09-06","current":-6.034663,"twenty":-8.411646,"median":-7.942728,"eighty":-7.024202,"marketCap":1217372976},{"date":"2024-09-13","current":-6.050501,"twenty":-8.400619,"median":-7.919793,"eighty":-6.989131,"marketCap":1217372976},{"date":"2024-09-20","current":-5.899508,"twenty":-8.390451,"median":-7.809695,"eighty":-6.977241,"marketCap":1194111072},{"date":"2024-09-27","current":-5.635763,"twenty":-8.383344,"median":-7.722148,"eighty":-6.974189,"marketCap":1147587264},{"date":"2024-10-04","current":-6.646499,"twenty":-8.371665,"median":-7.71452,"eighty":-6.971914,"marketCap":1347251940},{"date":"2024-10-10","current":-6.670566,"twenty":-8.369919,"median":-7.665604,"eighty":-6.970443,"marketCap":1343374956},{"date":"2024-10-18","current":-5.989499,"twenty":-8.366581,"median":-7.61103,"eighty":-6.964903,"marketCap":1199926548},{"date":"2024-10-25","current":-5.941495,"twenty":-8.363757,"median":-7.592567,"eighty":-6.963278,"marketCap":1190234088},{"date":"2024-11-01","current":-5.753759,"twenty":-8.362581,"median":-7.48471,"eighty":-6.932913,"marketCap":1153402740},{"date":"2024-11-08","current":-5.323409,"twenty":-8.352088,"median":-7.478194,"eighty":-6.706839,"marketCap":1062293616},{"date":"2024-11-15","current":-4.810927,"twenty":-8.344312,"median":-7.39462,"eighty":-6.66868,"marketCap":949861080},{"date":"2024-11-22","current":-4.597104,"twenty":-8.320901,"median":-7.288282,"eighty":-6.614502,"marketCap":907214256},{"date":"2024-11-29","current":-4.511723,"twenty":-8.314189,"median":-7.193914,"eighty":-6.4628,"marketCap":889767828},{"date":"2024-12-06","current":-3.832688,"twenty":-8.309887,"median":-7.189483,"eighty":-6.054759,"marketCap":754073388},{"date":"2024-12-13","current":-3.741546,"twenty":-8.30727,"median":-7.147179,"eighty":-6.049837,"marketCap":734688468},{"date":"2024-12-20","current":-3.946605,"twenty":-8.303428,"median":-7.141207,"eighty":-6.034627,"marketCap":771519816},{"date":"2024-12-27","current":-6.936731,"twenty":-8.302316,"median":-7.140369,"eighty":-6.034555,"marketCap":1355005908},{"date":"2025-01-03","current":-7.8123,"twenty":-8.301863,"median":-7.141207,"eighty":-6.034663,"marketCap":1527531696},{"date":"2025-01-10","current":-7.782302,"twenty":-8.301426,"median":-7.145546,"eighty":-6.036057,"marketCap":1515900744},{"date":"2025-01-17","current":-7.348445,"twenty":-8.300831,"median":-7.189317,"eighty":-6.042743,"marketCap":1432545588},{"date":"2025-01-24","current":-7.302687,"twenty":-8.300293,"median":-7.192391,"eighty":-6.047847,"marketCap":1432545588},{"date":"2025-01-28","current":-7.264616,"twenty":-8.299451,"median":-7.229265,"eighty":-6.049174,"marketCap":1432545588},{"date":"2025-02-07","current":-7.236748,"twenty":-8.296655,"median":-7.256521,"eighty":-6.050501,"marketCap":1418976144},{"date":"2025-02-14","current":-6.936954,"twenty":-8.289567,"median":-7.234585,"eighty":-6.050566,"marketCap":1356944400},{"date":"2025-02-21","current":-6.209204,"twenty":-8.280918,"median":-7.193914,"eighty":-6.051176,"marketCap":1221249960},{"date":"2025-02-28","current":-5.735312,"twenty":-8.276823,"median":-7.189483,"eighty":-6.049174,"marketCap":1124325360},{"date":"2025-03-07","current":-4.382772,"twenty":-8.275728,"median":-7.147179,"eighty":-6.034591,"marketCap":862628940},{"date":"2025-03-14","current":-4.381178,"twenty":-8.27337,"median":-7.141207,"eighty":-6.005336,"marketCap":862628940},{"date":"2025-03-21","current":-4.382899,"twenty":-8.271865,"median":-7.139645,"eighty":-5.976203,"marketCap":862628940},{"date":"2025-03-28","current":-6.03007,"twenty":-8.267559,"median":-7.132215,"eighty":-5.958282,"marketCap":1184418612},{"date":"2025-04-03","current":-12.27285,"twenty":-8.275893,"median":-7.137062,"eighty":-5.959979,"marketCap":1279404720},{"date":"2025-04-11","current":-11.044555,"twenty":-8.297306,"median":-7.141207,"eighty":-5.971601,"marketCap":1143710280},{"date":"2025-04-17","current":-8.683774,"twenty":-8.301426,"median":-7.143912,"eighty":-5.986226,"marketCap":901398780},{"date":"2025-04-25","current":-8.769575,"twenty":-8.306866,"median":-7.147536,"eighty":-5.989499,"marketCap":911091240},{"date":"2025-05-02","current":-8.750975,"twenty":-8.320901,"median":-7.189649,"eighty":-5.997241,"marketCap":911091240},{"date":"2025-05-09","current":-8.320184,"twenty":-8.320865,"median":-7.193914,"eighty":-5.999307,"marketCap":872321400},{"date":"2025-05-16","current":-7.720916,"twenty":-8.320762,"median":-7.234585,"eighty":-6.005336,"marketCap":816105132},{"date":"2025-05-23","current":-7.734459,"twenty":-8.320415,"median":-7.256521,"eighty":-6.010152,"marketCap":819982116},{"date":"2025-05-30","current":-7.700604,"twenty":-8.317297,"median":-7.263991,"eighty":-6.01222,"marketCap":819982116},{"date":"2025-06-06","current":-7.681007,"twenty":-8.314485,"median":-7.286363,"eighty":-6.02333,"marketCap":819982116},{"date":"2025-06-13","current":-9.456792,"twenty":-8.320762,"median":-7.288884,"eighty":-6.03007,"marketCap":1009954332},{"date":"2025-06-20","current":-9.38443,"twenty":-8.354671,"median":-7.302687,"eighty":-6.032718,"marketCap":1000261872},{"date":"2025-06-27","current":-8.886685,"twenty":-8.370356,"median":-7.33658,"eighty":-6.034591,"marketCap":949861080},{"date":"2025-07-04","current":-8.886268,"twenty":-8.400619,"median":-7.39462,"eighty":-6.034663,"marketCap":949861080},{"date":"2025-07-11","current":-9.439834,"twenty":-8.450162,"median":-7.477671,"eighty":-6.037451,"marketCap":1008015840},{"date":"2025-07-18","current":-10.71898,"twenty":-8.504633,"median":-7.483524,"eighty":-6.043853,"marketCap":1143710280},{"date":"2025-07-25","current":-10.354306,"twenty":-8.575353,"median":-7.586326,"eighty":-6.04851,"marketCap":1108817424},{"date":"2025-08-01","current":-10.200109,"twenty":-8.700378,"median":-7.607601,"eighty":-6.050501,"marketCap":1085555520},{"date":"2025-08-08","current":-10.174658,"twenty":-8.73051,"median":-7.6347,"eighty":-6.050545,"marketCap":1085555520},{"date":"2025-08-15","current":-10.189926,"twenty":-8.755577,"median":-7.668855,"eighty":-6.050988,"marketCap":1085555520},{"date":"2025-08-22","current":-10.404516,"twenty":-8.778653,"median":-7.696508,"eighty":-6.053156,"marketCap":1104940440},{"date":"2025-08-29","current":-12.496435,"twenty":-8.886268,"median":-7.699076,"eighty":-6.05556,"marketCap":1066170600},{"date":"2025-09-05","current":-12.508831,"twenty":-8.917527,"median":-7.704882,"eighty":-6.055623,"marketCap":1066170600},{"date":"2025-09-12","current":-12.713379,"twenty":-9.283082,"median":-7.709288,"eighty":-6.056629,"marketCap":1085555520},{"date":"2025-09-19","current":-13.812899,"twenty":-9.372197,"median":-7.711903,"eighty":-6.091088,"marketCap":1178603136},{"date":"2025-09-26","current":-15.488824,"twenty":-9.421871,"median":-7.713577,"eighty":-6.168118,"marketCap":1318174560},{"date":"2025-10-03","current":-15.429223,"twenty":-9.439834,"median":-7.716349,"eighty":-6.209251,"marketCap":1316236068},{"date":"2025-10-10","current":-15.542765,"twenty":-9.48241,"median":-7.718907,"eighty":-6.209438,"marketCap":1323990036},{"date":"2025-10-17","current":-15.463777,"twenty":-9.516549,"median":-7.722508,"eighty":-6.564001,"marketCap":1316236068},{"date":"2025-10-24","current":-16.141138,"twenty":-9.993637,"median":-7.727404,"eighty":-6.587794,"marketCap":1374390828},{"date":"2025-10-31","current":-15.935241,"twenty":-10.174658,"median":-7.732892,"eighty":-6.604283,"marketCap":1358882892},{"date":"2025-11-07","current":-15.945201,"twenty":-10.180758,"median":-7.758053,"eighty":-6.609789,"marketCap":1358882892},{"date":"2025-11-14","current":-15.900146,"twenty":-10.200109,"median":-7.784219,"eighty":-6.614502,"marketCap":1358882892},{"date":"2025-11-21","current":-16.089098,"twenty":-10.29964,"median":-7.809695,"eighty":-6.640318,"marketCap":1374390828},{"date":"2025-11-28","current":-16.030869,"twenty":-10.386607,"median":-7.849274,"eighty":-6.646499,"marketCap":1374390828},{"date":"2025-12-05","current":-16.003355,"twenty":-10.404516,"median":-7.919793,"eighty":-6.658209,"marketCap":1374390828},{"date":"2025-12-12","current":-15.973808,"twenty":-10.577045,"median":-7.942728,"eighty":-6.66868,"marketCap":1374390828},{"date":"2025-12-19","current":-15.93625,"twenty":-10.714182,"median":-7.97694,"eighty":-6.670691,"marketCap":1374390828},{"date":"2025-12-24","current":-15.662693,"twenty":-10.90375,"median":-7.980005,"eighty":-6.674625,"marketCap":1355005908},{"date":"2026-01-02","current":-17.543083,"twenty":-11.095447,"median":-7.982691,"eighty":-6.684863,"marketCap":1523654712},{"date":"2026-01-09","current":-17.49951,"twenty":-11.336885,"median":-7.988022,"eighty":-6.703505,"marketCap":1523654712},{"date":"2026-01-16","current":-17.442827,"twenty":-12.451475,"median":-7.994219,"eighty":-6.740071,"marketCap":1523654712},{"date":"2026-01-23","current":-17.215232,"twenty":-12.506134,"median":-8.02019,"eighty":-6.870823,"marketCap":1502331300},{"date":"2026-01-30","current":-17.402236,"twenty":-12.672793,"median":-8.041443,"eighty":-6.879903,"marketCap":1525593204},{"date":"2026-02-06","current":-16.762691,"twenty":-13.116393,"median":-8.071832,"eighty":-6.881774,"marketCap":1473253920},{"date":"2026-02-13","current":-15.877471,"twenty":-13.767462,"median":-8.141386,"eighty":-6.889262,"marketCap":1403468208},{"date":"2026-02-20","current":-15.900374,"twenty":-14.02108,"median":-8.157515,"eighty":-6.889266,"marketCap":1403468208},{"date":"2026-02-27","current":-15.727885,"twenty":-14.413548,"median":-8.177364,"eighty":-6.902973,"marketCap":1403468208},{"date":"2026-03-06","current":-12.483086,"twenty":-14.626023,"median":-8.18531,"eighty":-6.913266,"marketCap":1104940440},{"date":"2026-03-13","current":-12.425855,"twenty":-14.413548,"median":-8.193432,"eighty":-6.925983,"marketCap":1104940440},{"date":"2026-03-20","current":-12.823206,"twenty":-14.349192,"median":-8.196999,"eighty":-6.935617,"marketCap":1135956312},{"date":"2026-03-27","current":-9.060567,"twenty":-14.332776,"median":-8.234591,"eighty":-6.936865,"marketCap":800597196},{"date":"2026-04-02","current":-8.304746,"twenty":-14.318035,"median":-8.244293,"eighty":-6.936954,"marketCap":800597196},{"date":"2026-04-10","current":-9.618041,"twenty":-14.311841,"median":-8.248749,"eighty":-6.936954,"marketCap":934353144},{"date":"2026-04-17","current":-9.614004,"twenty":-13.827239,"median":-8.252895,"eighty":-6.946166,"marketCap":934353144},{"date":"2026-04-24","current":-9.573569,"twenty":-13.812899,"median":-8.25853,"eighty":-6.950948,"marketCap":930476160},{"date":"2026-04-30","current":-9.168948,"twenty":-13.631151,"median":-8.268259,"eighty":-6.958359,"marketCap":891706320},{"date":"2026-05-08","current":-8.743175,"twenty":-13.502409,"median":-8.275398,"eighty":-6.962537,"marketCap":852936480},{"date":"2026-05-15","current":-10.226462,"twenty":-13.419752,"median":-8.281283,"eighty":-6.963278,"marketCap":1000261872},{"date":"2026-05-22","current":-10.249888,"twenty":-13.229802,"median":-8.295352,"eighty":-6.963681,"marketCap":1000261872},{"date":"2026-05-29","current":-8.511974,"twenty":-13.133287,"median":-8.300714,"eighty":-6.963936,"marketCap":833551560},{"date":"2026-06-05","current":-8.301973,"twenty":-12.941558,"median":-8.301752,"eighty":-6.964084,"marketCap":814166640},{"date":"2026-06-12","current":-8.307592,"twenty":-12.828822,"median":-8.301973,"eighty":-6.964705,"marketCap":814166640},{"date":"2026-06-18","current":-7.893055,"twenty":-12.823206,"median":-8.301937,"eighty":-6.9664,"marketCap":775396800},{"date":"2026-06-26","current":-7.5352,"twenty":-12.80087,"median":-8.300843,"eighty":-6.968747,"marketCap":736626960},{"date":"2026-07-03","current":-7.529568,"twenty":-12.757166,"median":-8.299661,"eighty":-6.969565,"marketCap":736626960},{"date":"2026-07-10","current":-7.53882,"twenty":-12.715765,"median":-8.28571,"eighty":-6.970443,"marketCap":736626960},{"date":"2026-07-17","current":-7.512086,"twenty":-12.713379,"median":-8.276973,"eighty":-6.970666,"marketCap":736626960},{"date":"2026-07-24","current":-7.292992,"twenty":-12.672793,"median":-8.272018,"eighty":-6.97157,"marketCap":715303548},{"date":"2026-07-31","current":-7.279164,"twenty":-12.510448,"median":-8.264756,"eighty":-6.971614,"marketCap":715303548},{"date":"2026-08-07","current":-7.186303,"twenty":-12.508831,"median":-8.256463,"eighty":-6.971914,"marketCap":707549580},{"date":"2026-08-14","current":-7.078899,"twenty":-12.508831,"median":-8.250223,"eighty":-6.973489,"marketCap":697857120},{"date":"2026-08-21","current":-7.06329,"twenty":-12.507767,"median":-8.246013,"eighty":-6.973742,"marketCap":697857120}],"updateTime":1787456180668},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02496\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1145408618","title":"YZYBIO-B schedules 28 Aug 2026 board session to approve 1H 2026 interim results","url":"https://stock-news.laohu8.com/highlight/detail?id=1145408618","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145408618?lang=en_us&edition=fundamental","pubTime":"2026-08-18 16:48","pubTimestamp":1787042932,"startTime":"0","endTime":"0","summary":"Wuhan YZY Biopharma Co., Ltd. (YZYBIO-B, HKEX: 02496) has fixed 28 August 2026 for a board meeting aimed at reviewing and approving the company’s interim financial statements for the six months ended...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660682094","title":"Wuhan YZY Biopharma Schedules Board Meeting to Review Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2660682094","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660682094?lang=en_us&edition=fundamental","pubTime":"2026-08-18 16:41","pubTimestamp":1787042484,"startTime":"0","endTime":"0","summary":"Wuhan YZY Biopharma schedules board meeting to review interim resultsWuhan YZY Biopharma scheduled a board meeting for Aug. 28, 2026 to review interim results for the six months ended June 30, 2026.Di","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDL4WkK0p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132887864","title":"YZY Biopharma Reports No Change in Share Capital for July 2026; 1.25 Million Options Outstanding","url":"https://stock-news.laohu8.com/highlight/detail?id=1132887864","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132887864?lang=en_us&edition=fundamental","pubTime":"2026-08-05 16:48","pubTimestamp":1785919721,"startTime":"0","endTime":"0","summary":"Wuhan YZY Biopharma Co., Ltd. (YZY Biopharma) filed its Monthly Return for the period ended 31 July 2026, confirming that the company’s share structure remained stable during the month. Authorised...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162506633","title":"YZYBIO-B (02496) to Present Clinical Data for M701 at 2026 ASCO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1162506633","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162506633?lang=en_us&edition=fundamental","pubTime":"2026-05-22 20:08","pubTimestamp":1779451716,"startTime":"0","endTime":"0","summary":"YZYBIO-B (02496) has announced that clinical results from two studies of its core national Class 1 innovative drug M701, a \"CD3/EpCAM bispecific antibody,\" will be presented at the 2026 American...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637319080","title":"Wuhan YZY Biopharma says Phase III M701 trial prolongs puncture-free survival in malignant ascites","url":"https://stock-news.laohu8.com/highlight/detail?id=2637319080","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637319080?lang=en_us&edition=fundamental","pubTime":"2026-05-22 19:59","pubTimestamp":1779451164,"startTime":"0","endTime":"0","summary":"Wuhan Yzy Biopharma disclosed that results from two studies of its M701 CD3/EpCAM bispecific antibody will be presented at the 2026 ASCO Annual Meeting.A Phase III registrational study in malignant ascites showed M701 improved fluid control versus standard drainage, extended the time patients went without repeat procedures, and supported better reported quality of life.Overall survival was broadly similar between groups, while tolerability was described as comparable to the control arm.A randomized Phase II study in malignant pleural effusion linked to NSCLC showed stronger and more durable effusion control than drainage with or without local chemotherapy, with low rates of severe treatment-related side effects.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inves","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL5msJ4M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154204119","title":"YZYBIO-B Announces Supervisor Transition: Dr. Shi Jian Steps Down, Ms. Fang Lijuan Elected as Employee Representative","url":"https://stock-news.laohu8.com/highlight/detail?id=1154204119","media":"Bulletin Express","labels":["SGX","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154204119?lang=en_us&edition=fundamental","pubTime":"2026-05-15 16:43","pubTimestamp":1778834611,"startTime":"0","endTime":"0","summary":"Wuhan YZY Biopharma Co., Ltd. (YZYBIO-B) reported a change in its supervisory structure effective 15 May 2026. Employee representative supervisor Dr. Shi Jian has resigned for personal...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146997421","title":"YZYBIO-B (02496) Announces Election of Fang Lijuan as Second-Term Employee Representative Supervisor","url":"https://stock-news.laohu8.com/highlight/detail?id=1146997421","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146997421?lang=en_us&edition=fundamental","pubTime":"2026-05-15 16:37","pubTimestamp":1778834251,"startTime":"0","endTime":"0","summary":"YZYBIO-B (02496) has announced that Dr. Shi Jian has resigned from his position as employee representative supervisor due to personal career development reasons, effective May 15, 2026. Ms. Fang...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635670460","title":"Wuhan Yzy Biopharma names Fang Lijuan employee representative supervisor, replacing Shi Jian","url":"https://stock-news.laohu8.com/highlight/detail?id=2635670460","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635670460?lang=en_us&edition=fundamental","pubTime":"2026-05-15 16:33","pubTimestamp":1778834007,"startTime":"0","endTime":"0","summary":"Wuhan Yzy Biopharma named Fang Lijuan as employee representative supervisor, effective May 15, 2026.Fang is deputy director of Antibody Platform Department; she has 15 years of R&D experience in therapeutic antibodies, fusion proteins.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuhan Yzy Biopharma Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on May 15, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL9YhpZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02496"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158778344","title":"Wuhan YZY Biopharma’s NDA for Bispecific Antibody M701 Wins NMPA Acceptance","url":"https://stock-news.laohu8.com/highlight/detail?id=1158778344","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158778344?lang=en_us&edition=fundamental","pubTime":"2026-05-07 17:43","pubTimestamp":1778146988,"startTime":"0","endTime":"0","summary":"Wuhan YZY Biopharma Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has formally accepted the New Drug Application for M701, a self-developed bispecific antibody...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181865718","title":"YZYBIO-B Receives NMPA Acceptance for M701 New Drug Application Targeting Malignant Ascites","url":"https://stock-news.laohu8.com/highlight/detail?id=1181865718","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181865718?lang=en_us&edition=fundamental","pubTime":"2026-05-07 17:38","pubTimestamp":1778146700,"startTime":"0","endTime":"0","summary":"YZYBIO-B (02496) has announced that the New Drug Application for its self-developed bispecific antibody drug M701, intended for the treatment of malignant ascites caused by advanced epithelial...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","IPOS","02496"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633511173","title":"BRIEF-Wuhan Yzy Biopharma Co Says NDA For M701 Accepted By NMPA For Treatment Of Malignant Ascites","url":"https://stock-news.laohu8.com/highlight/detail?id=2633511173","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633511173?lang=en_us&edition=fundamental","pubTime":"2026-05-07 17:34","pubTimestamp":1778146466,"startTime":"0","endTime":"0","summary":"BRIEF-Wuhan Yzy Biopharma Co Says NDA For M701 Accepted By NMPA For Treatment Of Malignant AscitesMay 7 (Reuters) - Wuhan YZY Biopharma Co Ltd 2496.HK:NDA FOR M701 ACCEPTED BY NMPA FOR TREATMENT OF MALIGNANT ASCITESFurther company coverage: 2496.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nFWN41K0CJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633111739","title":"Wuhan YZY Biopharma says China regulator accepts M701 NDA for malignant ascites","url":"https://stock-news.laohu8.com/highlight/detail?id=2633111739","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633111739?lang=en_us&edition=fundamental","pubTime":"2026-05-07 17:34","pubTimestamp":1778146442,"startTime":"0","endTime":"0","summary":"Wuhan YZY Biopharma NDA for M701 accepted by China NMPA for treatment of malignant ascites caused by advanced epithelial tumors.Filing supported by Phase III China trial data; company plans to present results at 2026 ASCO annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuhan Yzy Biopharma Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on May 07, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL9BMkxL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633111205","title":"Wuhan YZY Biopharma Co Ltd - Nda for M701 Accepted by Nmpa for Treatment of Malignant Ascites","url":"https://stock-news.laohu8.com/highlight/detail?id=2633111205","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633111205?lang=en_us&edition=fundamental","pubTime":"2026-05-07 17:33","pubTimestamp":1778146422,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nFWN41K0CJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02496","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113166652","title":"YZYBIO-B Keeps Share Capital Steady in April; 1.25 Million H-Share Options Outstanding","url":"https://stock-news.laohu8.com/highlight/detail?id=1113166652","media":"Bulletin Express","labels":["SGX","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113166652?lang=en_us&edition=fundamental","pubTime":"2026-05-06 17:04","pubTimestamp":1778058292,"startTime":"0","endTime":"0","summary":"Wuhan YZY Biopharma Co., Ltd. (YZYBIO-B) reported no change in either authorised or issued share capital for the month ended 30 April 2026, according to its latest monthly return filed with the Hong...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152018804","title":"YZY Biopharma’s M701 Clinical Data Earns Dual Slots at 2026 ASCO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1152018804","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152018804?lang=en_us&edition=fundamental","pubTime":"2026-04-23 19:43","pubTimestamp":1776944612,"startTime":"0","endTime":"0","summary":"Wuhan YZY Biopharma Co., Ltd. (YZY Biopharma) disclosed that two pivotal studies for its core bispecific antibody candidate, M701, have been accepted for presentation at the 2026 American Society of...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192949223","title":"YZYBIO-B (02496): Two M 701 Research Findings Selected for Presentation at 2026 ASCO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1192949223","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192949223?lang=en_us&edition=fundamental","pubTime":"2026-04-23 19:41","pubTimestamp":1776944466,"startTime":"0","endTime":"0","summary":"Yuzhiyou Biotech-B (02496) has announced that two clinical research findings related to its core innovative bispecific antibody product, M 701, have been selected for presentation at the 2026...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02496"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629835095","title":"Wuhan YZY Biopharma says M701 Phase III malignant ascites data selected for ASCO oral presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2629835095","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629835095?lang=en_us&edition=fundamental","pubTime":"2026-04-23 19:34","pubTimestamp":1776944061,"startTime":"0","endTime":"0","summary":"Wuhan YZY Biopharma reported two clinical study readouts for its bispecific antibody M701 were selected for presentation at 2026 ASCO Annual Meeting, with results to be presented in the future.Phase III study in malignant ascites was slated for an oral session on May 31, 2026, signaling elevated conference visibility for program.Phase II study in non-small cell lung cancer-related malignant pleural effusion was scheduled for poster presentation on May 30, 2026, supporting potential expansion across malignant serous cavity effusion indications.M701 targets EpCAM and CD3 to redirect T cells to kill tumor cells, positioning asset as a differentiated supportive-care option in settings with limited treatment choices.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inves","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDLbFL5q3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166474674","title":"YZYBIO releases 2025 ESG report: RMB 78.20 million R&D spend, 9% drop in per-capita carbon emissions","url":"https://stock-news.laohu8.com/highlight/detail?id=1166474674","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166474674?lang=en_us&edition=fundamental","pubTime":"2026-04-16 23:09","pubTimestamp":1776352190,"startTime":"0","endTime":"0","summary":"Wuhan YZY Biopharma Co., Ltd. (YZYBIO, 02496) published its third Environmental, Social and Governance (ESG) report, covering the calendar year 2025 and prepared under the Hong Kong Stock Exchange...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141482640","title":"友芝友生物2025年收入下滑、研发投入减少并聚焦双特异抗体管线","url":"https://stock-news.laohu8.com/highlight/detail?id=1141482640","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141482640?lang=en_us&edition=fundamental","pubTime":"2026-04-16 23:09","pubTimestamp":1776352145,"startTime":"0","endTime":"0","summary":"武汉友芝友生物制药有限公司（以下简称“友芝友生物”，香港联交所股票代码：02496）于2025年继续深耕双特异抗体及相关创新药物研发，并披露了截至2025年12月31日的全年业绩和业务进展。根据公告，期内收入出现同比下降，研发投入减少，净亏损额有所收窄，公司整体资产负债状况由正转负，表明在商业化初期仍承受较大的研发与运营压力。 ■ 经营及财务表现...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627214319","title":"Wuhan YZY Biopharma publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2627214319","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627214319?lang=en_us&edition=fundamental","pubTime":"2026-04-16 22:59","pubTimestamp":1776351555,"startTime":"0","endTime":"0","summary":"Wuhan YZY Biopharma published its 2025 annual report, highlighting continued focus on bispecific antibody therapies for oncology-related complications.Lead asset M701 advanced in China, with Phase III malignant ascites trial enrollment completed in July 2025 at 312 patients; follow-up finished in March 2026 with data analysis ongoing.M701 malignant pleural effusion program moved through Phase Ib/II, with Phase II enrollment completed in September 2025 at 92 patients; interim results were presented at ESMO 2025.US expansion for M701 progressed, with FDA IND clearance for pleural effusion disclosed in February 2026.Pipeline execution broadened, with hemophilia candidate Y225 receiving China IND clearance in December 2025; Y101D pancreatic cancer Phase Ib/II study completed with CSR finalized in November 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gener","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL3pw2Py:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02496"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":30,"code":"91000000","status":"200"}]}}